AGENUS INC Revenue from Grants (Deprecated 2018-01-31)
AGENUS INC (AGEN) reported Revenue from Grants (Deprecated 2018-01-31) of $168.05 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-16.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromGrants · last filed 2018-03-16
- AGENUS INC revenue from grants (deprecated 2018-01-31) for the quarter ending 2014-12-31 was $102.34K.
- AGENUS INC revenue from grants (deprecated 2018-01-31) for the quarter ending 2014-09-30 was $343.15K.
- AGENUS INC revenue from grants (deprecated 2018-01-31) for the quarter ending 2014-06-30 was $29.97K.
- AGENUS INC revenue from grants (deprecated 2018-01-31) for the quarter ending 2014-03-31 was $28.77K.
- AGENUS INC revenue from grants (deprecated 2018-01-31) for fiscal 2017 was $168.05K, a 418.61% increase from fiscal 2016.
- AGENUS INC revenue from grants (deprecated 2018-01-31) for fiscal 2016 was $32.40K, a 34.36% increase from fiscal 2015.
- AGENUS INC revenue from grants (deprecated 2018-01-31) for fiscal 2015 was $24.12K, a 95.22% decline from fiscal 2014.
- AGENUS INC revenue from grants (deprecated 2018-01-31) for fiscal 2014 was $504.23K.
| Period end | Revenue from Grants (Deprecated 2018-01-31) 3 month | Revenue from Grants (Deprecated 2018-01-31) 6 month | Revenue from Grants (Deprecated 2018-01-31) 9 month | Revenue from Grants (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $168.05K 10-K · filed 2018-03-16 | |||
| 2016-12-31 | $32.40K 10-K · filed 2018-03-16 | |||
| 2015-12-31 | $24.12K 10-K · filed 2018-03-16 | |||
| 2014-12-31 | $102.34K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $445.49K derived: sum of 2 quarters · filed 2017-03-16 | $475.46K derived: sum of 3 quarters · filed 2017-03-16 | $504.23K 10-K · filed 2017-03-16 |
| 2014-09-30 | $343.15K 10-Q · filed 2014-10-31 | $373.12K derived: sum of 2 quarters · filed 2014-10-31 | $401.89K 10-Q · filed 2014-10-31 | $401.89K derived: sum of 4 quarters · filed 2015-03-16 |
| 2014-06-30 | $29.97K 10-Q · filed 2014-08-01 | $58.74K 10-Q · filed 2014-08-01 | $58.74K derived: sum of 3 quarters · filed 2015-03-16 | $58.74K derived: sum of 4 quarters · filed 2015-03-16 |
| 2014-03-31 | $28.77K 10-Q · filed 2014-05-09 | $28.77K derived: sum of 2 quarters · filed 2015-03-16 | $28.77K derived: sum of 3 quarters · filed 2015-03-16 | $28.77K derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $0.00 derived: sum of 2 quarters · filed 2015-03-16 | $0.00 derived: sum of 3 quarters · filed 2015-03-16 | $0.00 10-K · filed 2015-03-16 |
| 2013-09-30 | $0.00 10-Q · filed 2014-10-31 | $0.00 derived: sum of 2 quarters · filed 2014-10-31 | $0.00 10-Q · filed 2014-10-31 | |
| 2013-06-30 | $0.00 10-Q · filed 2014-08-01 | $0.00 10-Q · filed 2014-08-01 | ||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-09 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-16 | |||
| 2011-12-31 | $0.00 10-K · filed 2013-03-18 | |||
| 2010-12-31 | $424.72K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |